Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

This study has been completed.
Sponsor:
Collaborator:
Abbott
Information provided by (Responsible Party):
Vejle Hospital
ClinicalTrials.gov Identifier:
NCT01690598
First received: September 17, 2012
Last updated: June 9, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)